Chemours Co current report, 07 March 2016

Business Context and Reporting Period

This Form 8-K is a current report filed by The Chemours Company on March 7, 2016, regarding events that occurred on March 1, 2016. The filing details the grant of equity awards to named executive officers pursuant to The Chemours Company Equity and Incentive Plan.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.

Material Changes and Executive Compensation

On March 1, 2016, the company granted non-qualified stock options and performance share units to five named executive officers. The stock options have an exercise price of $5.40 and vest ratably over three years with a ten-year term. The performance share units are contingent on meeting Adjusted EBITDA and Pre-Tax Return on Invested Capital goals over a three-year period (2016-2018), with potential adjustments based on Relative Total Shareholder Return.

ExecutivePositionStock Options GrantedPerformance Share Units (Target)
Mark P. VergnanoPresident and CEO543,944310,672
Mark E. NewmanSVP and CFO166,08994,862
E. Bryan SnellPresident—Titanium Technologies110,72663,242
Elizabeth AlbrightSVP—Human Resources69,20439,526
Thierry F.J. VanlanckerPresident—Fluoroproducts48,52327,715

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency noted is that the vesting of performance share units is subject to the satisfaction of specific financial performance goals and shareholder return metrics.

Key Facts for Investor Verification

  • Verify the current stock price relative to the $5.40 exercise price of the newly granted options.
  • Review the specific Adjusted EBITDA and Pre-Tax Return on Invested Capital targets defined in the performance share unit terms.
  • Confirm the total dilution impact of the 938,486 stock options and 536,017 performance share units granted.
  • Check subsequent filings for any modifications to the performance metrics or vesting schedules.